呼吸喹诺酮类抗菌药物评介

被引:13
作者
何礼贤
机构
[1] 复旦大学附属中山医院、复旦大学呼吸病研究所上海
关键词
喹诺酮类药物; 肺炎,社会获得性; 支气管炎,慢性;
D O I
暂无
中图分类号
R560.5 [];
学科分类号
1002 ; 100201 ;
摘要
新一代喹诺酮类药物中左氧氟沙星、加替沙星、莫西沙星和吉米沙星抗肺炎链球菌等G+ 球菌活性显著提高 ,被称为“呼吸”喹诺酮类药物。该文就其抗菌作用和药效学特点、治疗下呼吸道感染的疗效和安全性、在社区获得性下呼吸道感染治疗的地位与争议进行评介 ,并对防止耐药要求寻找和制订更合理用药方案以使血清或组织浓度达到“防突变”浓度扼要予以讨论。
引用
收藏
页码:21 / 23
页数:3
相关论文
共 8 条
[1]  
Fluoroquinolones as pneumococcal therapy: Closing the barn door before the horse escapes. Tillotson G,Zhao X,Drilica K. The Lancet Infectious Diseases . 2001
[2]  
Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. Ball P,Wilson R,Mandell L,et al. Journal of Chemotherapy . 2001
[3]  
Guidelines for the management of adults with community-acquired pneumonia. Amer Thorac Society. American Journal of Respiratory and Critical Care Medicine . 2001
[4]  
A prospective, randomized,double-blind study treating community-acquired pneumonia in hospitalized patients: gatifloxacin VS ceftriaxone clarithromycin. Forgarty C,Dowell M E,Ellison WT,et al. Journal of Respiratory Diseases . 1999
[5]  
Clinician’s Manual on Respiratory Tract Infections and Fluoroquinolones. Read R C,Morrissey I,Ambler J E,et al. . 2000
[6]  
A double-blind, randomized study of safety and efficacy treating community acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. Sullivan J G,McElroy A,Honsinger R W. et al. Journal of Respiratory Diseases . 1999
[7]  
Relative potential for selection of fluoroquinolone-resistant streptococcus pneumoniae strains by levofloxacin:comparison with ciprofloxacin, sparfloxacin and ofloxacin. Drugeon H B,Juvin M E,Bryskier. Journal of Antimicrobial Chemotherapy . 1999
[8]  
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized,double-blind comparison with trovafloxacin. File T M Jr,Schlemmer B,Garau J,et al. Journal of Antimicrobial Chemotherapy . 2001